BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering

BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement
Offering

LYNBROOK, N.Y., Jan. 14 /PRNewswire-FirstCall/ -- BioSpecifics
Technologies Corp. (Pink Sheets: BSTC.PK) today announced that it sold 200,000
unregistered shares of its common stock, in a private placement offering to an
investment fund, at a purchase price of $10.50 per share for aggregate
proceeds to the Company of $2,100,000.
About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has
developed and licensed injectable collagenase for three clinical indications.
We have a development and licensing agreement with Auxilium Pharmaceuticals
for clinical indications in Dupuytren's disease, Peyronie's disease and frozen
shoulder (adhesive capsulitis). The indication for Dupuytren's disease is in
Phase III trials.
BioSpecifics web site is:
http://www.biospecifics.com
SOURCE BioSpecifics Technologies Corp.

Tom Wegman, BioSpecifics Technologies Corp., +1-516-593-7000